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ration. Drug Intell Clin
SUMMARY
This thesis examines the manner in which drug uti l ization data obtained from com-
munity pharmacies can contribute to a safe and rational use of drugs shortly before
and during pregnancy. Three studies were performed with this goal in mind. The
first study is based on data relating to 1,948 women obtained from 10 community
pharmacies in the north of The Netherlands;it describes the use of prescribed drugs
before, during and after pregnancy. In the second study 295 mothers were inter-
viewed a few days after delivery about the medication which they had used during
pregnancy. The third study describes the use of ovulation-stimulating drugs in the
Dutch population.
In chapter 1 the background and goalof the studies are given. The history of drug
registration in most developed countries is strongly influenced by the thalidomide
(Softenon) disaster. This case and other experiences with drugs led drug regula-
tory authorities to demand a series of extensive animal and clinical/toxicological
investigations which should be performed before a drug can be registered. Unfor-
tunately however, these procedures -although they offered an adequate approach
to the question of drug safety in general- fail to solve the problem which has led to
their introduction, i.e. the safe use of drugs in pregnancy. We realise that knowl-
edge about the safety of drug use related to pregnancy is limited. Data obtained
from animal studies are of marginal value for predicting the safety of drugs in hu-
man pregnancy. Moreover, for obvious ethical reasons, pregnancy is a contraindi-
cation for clinical investigations with new drugs. It thus follows that, in almost every
instance, new drugs are necessarily released onto the market without any knowl-
edge on its safety in human pregnancy. In spite of this, it is evident that the large
majority of available drugs will, sooner ar later, be used in pregnant women; not
uncommonly, risks are taken under uncontrolled conditions. Knowledge about the
safety and efficacy of a drug is thus gradually derived from experience in practíce.
In the wHo report "Drugs in pregnancy and delivery" it was stated that: "Expei-
ments in human teratogenicity are going on all the time but the results are not being
studied." Therefore a systematic evaluation of drugs used in relation to pregnancy
is of high importance.
In chapter 2 the method of data collection and the characteristics of the drug
utilization data from community pharmacies are described. Our data reflect the
general prescribing pattern for pregnant Dutch women who have delivered a live-
born baby. Various measures to evaluate drug exposure are used. The'prescription
Íate', defined as the number of women per 1,000who received at least one pre-
scription of a given drug, is a fair estimate of prescribing behaviour of the medical
profession. While the'exposure rate', defined as the number of women per 1,000
to whom a given drug is available, is more useful in terms of possible risks for the
foetus, because the duration of the prescription is taken into account.
During the course of pregnancy the use of drugs was found to have increased
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even when iron preparations and vitamins -the most used drugs- were not taken
into account. Most of the women (737o) received one or more iron prescriptions
during the course of pregnancy in a low daily dose. The use of antiemetics, antacids,
laxatives and treatment for vaginal infections showed a relative increase, whereas
the use of cardiovascular, antiinflammatory and central nervous system drugs de-
creased during pregnancy. At least one percent of the women filled a new prescrip-
tion for contraceptives in the first trimester of pregnancy. It seems feasible to use
pharmacy records as a data base to obtain reliable epidemiological information on
drug use during pregnancy. However these pharmacy records have their shortcom-
ings. On the one hand, figures may be underestimated since drugs during hospital
stay and over-the-counter drugs are not included. On the other hand, some figures
may be overestimated since we do not know to what extent drugs dispensed by the
pharmacy are actually consumed.
In chapter 3 the data obtained directly from the women by interview are pre-
sented. [n order to validate further the pharmacy data we init iated a complemen-
tary study, in which women were interviewed shortly after delivery of their babies
about drug use in pregnancy; at the same time we collected the pharmacy records
of these same women, after obtaining informed consent. This study is part of the
international "Collaborative study on drug use in pregnancy"; we therefore used
the international questionnaire. In this questionnaire only open-ended questions
were used to collect drug exposure data. From other studies it is known that in-
sufficient recall may occur and that reported drug use varies according to the type
of questioning and is directly related to the specificity of the questions asked. We
therefore extended this questionnaire with two additional, more specific questions:
an indication-oriented and a drug-oriented one. The results of this comparison are
discussed. The proportion of self-medication drugs reported increased from 22Vo
after the open-ended to 31o/a after the more specific questions. Only one out of
the nine women who were sti l l  using oral contraconceptives in early pregnancy re-
ported this use in the open-ended question. These findings suggest that if drug
consumption during pregnancy is evaluated by interview one should not restrict
oneself to the open-ended questions, but should include indication-oriented and,
as far as desired and possible, drug-oriented questions as well.
The comparison of data from pharmacy records with data obtained from inter-
views of the mother are presented in chapter 4. After excluding the reported self-
medication drugs from the interview data, no difference was found between the
two sources with respect to the mean number of drugs used per woman. Agree-
ment with respect to the exact number of drugs received per woman was, however,
very low (427c with a kappa value of 0.28). Poor agreement was related to a higher
percentage of users according to interview data in the case of analgesics, vitamins
and non-official drugs whereas in the case of dermatological and respiratory drugs
and eyelear preparations a higher percentage of consumers was found when using
pharmacy data. Good agreement was found for the antacids, iron preparations, an-
tibiotics and drugs for vaginal infections. At least one quarter of all prescriptions
























































































having followed the instructions adequately. We conclude that the two methods of
data collection are clearly complementary to each other.
In chapter 5 and ó the prescription records of 1,948 Dutch women were set
against the Australian classification of drugs with respect to their known or sus-
pected risk in pregnancy. During pregnancy the use of drugs with proven or anti-
cipated fetal toxicity appears to decrease, indicating that the medical profession is
relatively well aware of these potential sidc effects. In the case of antibiotics the
fall in the use of potentially fetal toxic drugs is due to a shift to relatively less fe-
tal toxic drugs whereas the decreased use of analgesics and some antirheumatic
drugs is not accompanied by replacement by others. The prescnt study shows that
in spite of the generally favourable trends, 168 out of 1000 women received during
the course of pregnancy one or more prescriptions from the higher risk categories.
When the pattern of changes in use of these drugs was studied in terms of women
who stop (s), continue (c) or begin (b) using the drug during pregnancy, the ratios
si(c+b) and s/b were the highest for the drugs belonging to the high risk categories
and the lowest for drugs from thc low risk categories. The data from this analy-
sis indicate that the prescribing physician is generally aware of the possible risks of
drug use during pregnancy. The s/(b+c) and s,/b ratios are shown to be a good mea-
sure of prescribing behaviour in relation to pregnancy and can be used to compare
knowledge of theorv with daily practice.
Viewed against the background outl ined above, an additional study is presented
in chapter 7, in which one particular treatment under suspicion of exerting terato-
genic effects is analyzed, namely the use of ovulation-stimulating drugs in a repre-
sentative sample of a population of Dutch women. Several authors have reported
a possible association between ovulation induction on the one hand and the oc-
currence of neural tubc defects and neuro-ectodermal tumours on the other hand.
This study gives us the opportunity to estimate the number of cases of neural tube
defects and the number of neuro-ectodermal tumours attributable to ovulation in-
duction. Clomiphene, the most frequently used ovulation-inducing drug, is seldom
used alone. A considerable percentage of the women received at least four different
ovulation-inducing and related drugs during the observation pcriod of two years.
Thirty percent of the women who used clomiphene were treated for 6 or more
cycles. These findings argue for a rclative "overuse" of clomiphene. Buserelin, a
drug not registered for the indication ovulation induction in The Netherlands but
used in in vitro ferti l ization (tvr) programs, was neverthe less frequently prescribed
to these women. This study indicates that, though the potential risks of congeni-
tal malformations due to ovulation induction are diff icult to assess, they may be
considerable; this, and the fact that different ovulation-inducing drugs are used
together with clomiphcne, emphasizcs the need for post-marketing surveil lance.
Finally, in the last chapter we focused on the basic question posed in the tit le
of this thesis: "Can drug uti l ization studies cclntributc to the safe use of drugs in
pregnancy?" Our study was a retrospective onc, in that the woman was selected for
inclusion only after the birth of a l ive child. Thc data which can be mobil ized in this
way prove so informative, and the process of mobil izing them is so cost-cffective
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that the method can be recommended for a more widespread use. With some sim-
ple supplementation this technique might well be used on a prospective and contin-
uous basis, subject to agreement between the individual pharmacist, the individual
physician, the midwife and the woman herself. Consent by the woman is needed to
allow the pharmacist to be informed of the woman's pregnancy at an early stage.
It wil l provide the opportunity to evaluate prescribing behaviour very closely, and
the latter can then be discussed in pharmacotherapeutic onsultation between the
pharmacist and physician in order to promote safe drug use in pregnancy. In addi-
tion, drug uti l ization data from a series of individual community pharmacies, taken
together, create a valuable data base for pharmaco-epidemiological studies in the
conrmunity. By combining such drug utilization studies with data from registries
of congenital abnormalit ies one wil l be able to develop the fund of knowledge and
the classification of drugs with respect to their risks in pregnancy can be assured to
be as accurate as it can reasonably be.
This study has centred largely on the role which pharmacy data can play in study-
ing, monitoring and optimalizing drug use in pregnancy, but in essence the lessons
to be derived from it may well prove to be of much broader application. Where
high risk groups are concerned, be they pregnant women, children, the eldery, in-
valids or others with a particular susceptibil i ty to drug injury, there is a need for
ever bette r routines to ensure that data on drug use and drug risk are available, are
understood and are properly used to patient's benefit. In that process, essentially
a mutual one involving the physician, the pharmacist and the patient, the commu-
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